Novonesis A/S Class B NSIS_B
OMXCOP · Denmark · Process Industries
DKK 415.40-4.10 (-0.98%)
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Investment increases production capacity, supports booming consumer demand and reinforces Wisconsin's leadership in dairy biosolutions West Allis Ribbon Cutting Anders Lund, Chief Operating Officer and Executive Vice President at Novonesis cuts the ribbon at the West Allis ceremony. West Allis Ribbon Cutting Group photo at the Novonesis West Allis ribbon cutting on Friday, September 25 WEST ALLIS, Wis., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Novonesis, a global leader in biosolutions, announced the
Expansion in Patalganga puts Novozymes under the spotlight Novozymes (CPSE:NSIS B) has come into focus after Novonesis announced a €600 million plan to expand its Patalganga site, with the aim of increasing biosolutions capacity for customers across high growth markets. For context, Novozymes shares last closed at DKK429.4. A 90-day share price return of 13.00% points to building momentum, even though the 1-year total shareholder return of 8.50% and the 5-year total shareholder return, which...
Today, Novonesis will initiate the first tranche (the “First Tranche”) of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the First Tranche, Novonesis will acquire B shares for an aggregate amount of up to EUR 75 million, with the First Tranche expected to end no later than December 17, 2026. Based on the closing share price on September 11, 2026, the First Tranche corresponds to around 1.3 million B shares. The shares acquir
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.